University of Manitoba independent research verifies that RuvidarTM is more effective than acyclovir in the inactivation of Herpes Simplex Viruses post infection. TORONTO, ON / ACCESS Newswire ...

Clinical-stage pharma stock Theralase Technologies (TSXV:TLT) announced a significant breakthrough in the treatment of Herpes ...

University of Manitoba independent research verifies that RuvidarTM is more effective than acyclovir in the inactivation of Herpes Simplex Viruses post infection. TORONTO, ON / ACCESS Newswire / ...

Detailed price information for Theralase Technologies Inc (TLTFF) from The Globe and Mail including charting and trades.

University of Manitoba independent research verifies that Ruvidar TM is more effective than acyclovir in the inactivation of Herpes Simplex Viruses post infection. TORONTO, ON / ACCESS Newswire / ...